| Withdrawn | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcin NCT02295540 | Rutgers, The State University of New Jersey | N/A |
| Completed | Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoi NCT02123511 | Mayo Clinic | Phase 2 |
| Withdrawn | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Ra NCT01728480 | Roswell Park Cancer Institute | Phase 1 |
| Withdrawn | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiatio NCT01674374 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137 | Stanford University | Phase 1 |
| Withdrawn | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma NCT01465815 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC NCT01283178 | Virginia Commonwealth University | Phase 1 |
| Completed | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177 | University of Washington | Phase 1 |
| Terminated | Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer NCT01254734 | City of Hope Medical Center | N/A |
| Terminated | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck NCT01192815 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radi NCT01164566 | Wake Forest University Health Sciences | N/A |
| Completed | L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For NCT01155609 | University of Washington | N/A |
| Terminated | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receivin NCT01682031 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Cau NCT00895245 | University of Washington | Phase 2 |
| Terminated | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck NCT01473784 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri NCT00492089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral NCT01504932 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or NCT00410826 | University of Washington | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the NCT00081211 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer NCT00049166 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Ca NCT00055770 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head NCT00033449 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer NCT00896961 | National Cancer Institute (NCI) | N/A |
| Completed | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity NCT02119728 | Roswell Park Cancer Institute | Phase 2 |